Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan-Feb;12(1):80-93.
doi: 10.1097/APO.0000000000000596. Epub 2023 Jan 12.

Applications of Artificial Intelligence and Deep Learning in Glaucoma

Affiliations
Free article

Applications of Artificial Intelligence and Deep Learning in Glaucoma

Dinah Chen et al. Asia Pac J Ophthalmol (Phila). 2023 Jan-Feb.
Free article

Erratum in

Abstract

Diagnosis and detection of progression of glaucoma remains challenging. Artificial intelligence-based tools have the potential to improve and standardize the assessment of glaucoma but development of these algorithms is difficult given the multimodal and variable nature of the diagnosis. Currently, most algorithms are focused on a single imaging modality, specifically screening and diagnosis based on fundus photos or optical coherence tomography images. Use of anterior segment optical coherence tomography and goniophotographs is limited. The majority of algorithms designed for disease progression prediction are based on visual fields. No studies in our literature search assessed the use of artificial intelligence for treatment response prediction and no studies conducted prospective testing of their algorithms. Additional challenges to the development of artificial intelligence-based tools include scarcity of data and a lack of consensus in diagnostic criteria. Although research in the use of artificial intelligence for glaucoma is promising, additional work is needed to develop clinically usable tools.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Similar articles

Cited by

References

    1. Miller M FDA publishes approved list of AI/ML-enabled medical devices. IQVIA 2022. Accessed July 30. https://www.iqvia.com/locations/united-states/blogs/2021/10/fda-publishe...
    1. US Food and Drug Administration. De novo classification request for IDX-DR. US Food and Drug Administration. 2018. https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN180001.pdf
    1. US Food and Drug Administration. EyeArt 510(k) Summary (K200667). US Food and Drug Administration. 2020. Accessed August 21, 2021. https://www.accessdata.fda.gov/cdrh_docs/pdf20/K200667.pdf
    1. Tham YC, Li X, Wong TY, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121:2081–2090.
    1. Shaikh Y, Yu F, Coleman AL. Burden of undetected and untreated glaucoma in the United States. Am J Ophthalmol. 2014;158:1121–1129.